Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT02339064
PHASE3

Infusion of Apomorphine: Long-term Safety Study

Sponsor: MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals

View on ClinicalTrials.gov

Summary

This is a Phase 3, multicenter, open-label, safety and tolerability study of continuous apomorphine infusion in subjects with advanced Parkinson's Disease (PD) whose motor fluctuations remain unsatisfactory with levodopa (or levodopa/carbidopa) and at least one other class of drugs or mode of therapy for PD.

Official title: A Phase 3, Open-Label Study of the Safety, Efficacy and Tolerability of Apomorphine Administered by Continuous Subcutaneous Infusion in Advanced Parkinson's Disease Patients With Unsatisfactory Control on Available Therapy

Key Details

Gender

All

Age Range

30 Years - Any

Study Type

INTERVENTIONAL

Enrollment

99

Start Date

2015-02

Completion Date

2025-12

Last Updated

2025-06-19

Healthy Volunteers

No

Interventions

DRUG

apomorphine infusion

Treatment with apomorphine provided by continuous subcutaneous infusion using a portable external electronic pump device

Locations (18)

Phoenix, Arizona, United States

Loma Linda, California, United States

Los Angeles, California, United States

Los Angeles, California, United States

Aurora, Colorado, United States

Englewood, Colorado, United States

Boca Raton, Florida, United States

Atlanta, Georgia, United States

Augusta, Georgia, United States

Chicago, Illinois, United States

Chicago, Illinois, United States

Kansas City, Kansas, United States

West Bloomfield, Michigan, United States

Albany, New York, United States

Cincinnati, Ohio, United States

Portland VA Medical Center

Portland, Oregon, United States

Philadelphia, Pennsylvania, United States

Kirkland, Washington, United States